Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib (Q37952231)

25 August 2017

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib (English)

1 reference

25 August 2017

0 references

hepatocellular carcinoma

1 reference

Giuseppe Cabibbo

1

1 reference

25 August 2017

Emanuela Rolle

2

1 reference

25 August 2017

Massimo De Giorgio

3

1 reference

25 August 2017

Chiara Genco

4

1 reference

25 August 2017

Tiziana Pressiani

5

1 reference

25 August 2017

Francesca Spada

6

1 reference

25 August 2017

Rodolfo Sacco

7

1 reference

25 August 2017

HCC Working Group

8

1 reference

25 August 2017

26 August 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

1 reference

25 August 2017

11

1 reference

25 August 2017

12

1 reference

25 August 2017

1807-1816

1 reference

Global cancer statistics, 2002

25 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Non-alcoholic steatohepatitis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Updated treatment approach to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Hepatocellular cancer: optimal strategies for screening and surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Major achievements in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.139

21 January 2018

Identifiers

DOI

10.1586/ERA.11.139

1 reference

25 August 2017

1 reference